Background and Objective: Prostate cancer is an endocrine-dependent tumor which is still under-investigated for physiopathology factors related to its natural history. The association of pretreatment total testosterone (TT) serum levels with prostate cancer is still a controversial topic. The objective of this study was to investigate potential associations and functional relationships of preoperative TT serum level and pathology-detected Gleason score (pGS). Materials and Methods: Pretreatment and pathological variables of 220 patients operated with radical prostatectomy were retrospectively reviewed. Age, prostate-specific antigen (PSA), percentage of positive biopsy cores (P+), biopsy Gleason score (bGS), pGS, TT and free testosterone were the continuous variables, while clinical stage (cT: cT1c, cT2/3), biopsy Gleason pattern (bGP: ≤3+3, 3+4, >3+4), pathology Gleason pattern (pGP: ≤3+3, 3+4, >3+4), pathology stage (pT: pT2, pT3a, pT3b), pathology nodal staging (pN: pN0, pN1, pNx) and surgical margin invasion by cancer (R-, R+) were the categorical variables. Statistical methods were computed for assessing associations of TT and pGS; moreover, simple and multiple linear regression analysis (SLRA and MLRA) were used for assessing functional relationships of TT and pGS. Results: High-grade tumors (pGS ≥8.0) were associated with bGS >6.0 (p < 0.0001), pGP ≥3+4 (p < 0.0001), P+ >0.31% (p = 0.006), cT2/3 (p = 0.01), TT >15.5 nmol/l (p = 0.0004) and, to a lesser extent, PSA >6.27 μg/l (p = 0.06). The odds ratio (OR) ranked as follows: 2.01 (PSA >6.27 μg/l), 2.88 (cT2/3), 3.23 (P+ >0.31%), 5.53 (TT >15.5 nmol/l) and 12.09 (pGP ≥3+4 and pGS ≥8.0). On SLRA, pGS variation was significantly predicted by bGS (p < 0.0001), P+ (p < 0.0001), PSA (p = 0.0005) and TT (p = 0.02); on MLRA, pGS variation was still significantly predicted by bGS (p < 0.0001), P+ (p = 0.04), PSA (p = 0.03) and TT (p = 0.002). When bGS, P+, PSA and TT were dichotomized to their median value, only bGS (p < 0.0001) and TT (p = 0.001) showed independence in predicting pGS variation. The best model for predicting pGS variations was by dichotomizing TT above its median (>15.5 nmol/l) because the predictive coefficient increased to 0.32, which means that patients with TT >15.5 have a significantly higher estimated risk for high-grade pGS than patients with TT ≤15.5 nmol/l (OR = 1.31). Conclusion: In a patient population undergoing radical prostatectomy, increased pretreatment serum measurements of TT are associated with and functionally related to high-grade pGS; moreover, baseline TT together with bGS and PSA are important factors for predicting pGS and assessing high-grade tumors. Baseline TT serum levels might have prognostic potential for assessing treatment response for continuous as well as intermittent androgen deprivation therapy.

Keywords:
Total testosterone, Free testosterone, Prostate-specific antigen, Prostate cancer, Biopsy Gleason score, Pathology-detected Gleason score
1.
Huggins C, Hodges CV: Studies on prostate cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
3.
Armbruster DA: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993;39:181-195.
4.
Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC: Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449-453.
5.
Olsson M, Ekstrom L, Schulze J, Kjellman A, Akre O, Rane A, Gustafsson O: Radical prostatectomy: influence on serum and urinary androgen levels. Prostate 2010;70:200-205.
6.
Harper ME, Pierrepoint CG, Griffiths K: Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984;20:477-482.
7.
Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 2002;89:710-713.
8.
Hammond GL, Kontturi M, Maattala P, Puukka M, Vihko R: Serum FSH, LH, prolactin in normal males and patients with prostatic diseases. Clin Endocrinol 1977;7:129-135.
9.
Kumar VL, Wafhwa SN, Kumar V, Farooq A: Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 1990;44:122-128.
10.
Hilz H, Graefen M, Noldus J, Hammerer P, Knabbe C, Huland E, Huland H: Advanced prostate cancer is associated with a decrease in serum luteinizing hormone. Eur Urol 2000;38:243-249.
11.
Madersbacher S, Shatzl G, Bieglmayer C, Reiter BW, Gassner C, Berger P, Zidek T, Marberger M: Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal axis. Urology 2002;60:869-874.
12.
Fodstad P, Bjoro T, Torlakovic G, Fossa SD: No association of serum gonadal or pituitary hormone with prognostic parameters in stages T1 to T3 pN0M0 prostate cancer. J Urol 2002;168:1188-1192.
13.
Pound CR, Partin AW, Eisenberger M, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
14.
Hull GW, Rabbani F, Abbas FA, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-534.
15.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-439.
16.
Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino P; Transatlantic Prostate Group: Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006;95:1186-1194.
17.
Monda JM, Myers RP, Bostwick DG, Oesterling JE: The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology 1995;46:62-64.
18.
Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y, Muto S, Horie S: Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res 2008;28:2487-2492.
19.
Anderson SO, Adami HO, Bergstrom R, Wide B: Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population-based case control study. Br J Cancer 1993;68:97-102.
20.
Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52-58.
21.
Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
22.
Mikkola AK, Aro JL, Rannikko SA, Salo JO: Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostate cancer. FINNPROSTATE group. Prostate 1999;39:175-181.
23.
Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F: Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer 2011;117:5029-5038.
24.
Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK: Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 2009;73:356-361.
25.
Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K: Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: tumor malignant potential and androgen milieu. Prostate 2010;70:1395-1401.
26.
Hoffman MA, Dewolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000;163:824-827.
27.
Zhang PL, Rosen S, Veeramachaneni R, Kao J, Dewolf WC, Bubley G: Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179-182.
28.
Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008;72:1240-1245.
29.
Røder MA, Christensen IJ, Berg KD, Gruschy L, Brasso K, Iversen P: Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int 2012;109:520-524.
30.
Flemming ID, Cooper JS, Henson DE, Hutte RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JN (eds): American Joint Committee on Cancer Staging Manual, ed 5. Philadelphia, JP Lippincott, 1997, pp 219-222.
31.
Dai B, Qu Y, Kong Y, Ye D, Yao X, Zhang S, Wang C, Zhang H, Yang W: Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer. BJU Int 2012;110:E667-E672.
32.
Mearini L, Zucchi A, Nunzi E, Villirillo T, Bini V, Porena M: Low serum testosterone levels are predictive of prostate cancer. World J Urol 2013;31:247-252.
33.
Porcaro AB, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B, Cocco C, Romano M, Artibani W: Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups. Anticancer Res 2012;32:5015-5022.
34.
Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, Colombo R, Ferrari M, Castagna G, Rigatti P, Montorsi F: Serum sex steroids depict a nonlinear U-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res 2012;18:3648-3657.
35.
Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB: Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 2010;105:824-829.
36.
Albisinni S, De Nunzio C, Tubaro A, Barry WT, Banez LL, Fredland SJ: Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology 2012;80:162-167.
37.
Ghanadian R, Puah CM, O'Donoghue EP: Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 1979;39:696-699.
38.
Corcoran NM, Gleave ME: Targeted therapy in prostate cancer. Histopathology 2012;60:216-231.
39.
Abrahamsson PA: Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
40.
Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais Da Silva F: Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-730.
41.
Shore N, Crawford D: Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 2005;12:1-11.
42.
Oefelin MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI: Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021-1024.
43.
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group: The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187:2074-2081.
44.
Gleave M, Klotz I, Taneja SS: The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 2009;27:81-86.
45.
Klotz L: Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer. Curr Urol Rep 2013;14:159-167.
46.
Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA, Morote J: Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int 2013;90:41-44.
47.
Porcaro AB, Migliorini F, Petrozziello A, Sava T, Romano M, Caruso B, Cocco C, Ghimenton C, Zecchini Antoniolli S, Lacola V, Rubilotta E, Monaco C, Comunale L: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy. Urol Int 2013;90:45-55.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.